Docs prefer e-detailing slightly less in 2009

Share this article:
The number of physicians who like e-detailing dipped nearly 10% from 2008 to 2009, according to a recent study.

Fifty-eight percent reported feeling positively or very positively about e-marketing, down from 67% in 2008. Results are based on answers from about 1,200 tech-savvy doctors in 15 specialties. “The majority were still positive, but a greater percentage were either neutral or negative,” said Melissa Leonhauser, director of strategic marketing for SDI, which fields the ePromotion attitudinal study every October. SDI defines ePromotion as video details, online events and virtual details.

On the positive side, more said that ePromotion was inferior to the face-to-face kind (34% in 2009 vs. 27% in 2008), although the majority continued to regard the two equally well and slightly more were replacing face-to-face with online. Also, compared to 2008, physicians said they were more likely to take action after participating in ePromotion, including request samples, watch a video or podcast or conduct research.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?